This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, C-N Articles by Tsay, G J Search for Related Content PubMed PubMed Citation Articles by Huang, C-N Articles by Tsay, G J Social Bookmarking                   What's this?

Anti-nuclear antibody, anti-DNA, and aCL in Graves’ disease patients treated with propyluracil or methimazole

Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC, Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC

T-C Hsu

Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC, Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC

H-H Chou

Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC, Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC

G J Tsay

Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC, Institute of Immunology, Chung Shan Medical University Hospital, Taichung, Taiwan, ROC, gjt{at}csmu.edu.tw

One hundred and forty patients with Graves’disease [32 new patients, 54 treated with propylthiouracil (PTU) for a mean of 27.2 months and 54 treated with methimazole (MMI) for a mean of 48.6 months] were tested for anti-thyroid microsomal antibody (AMA), anti-thyroglobulin antibody (ATA), thyroid binding inhibitory immunoglobulin (TBII), and the non organ specific autoantibodies [i.e., anti-nuclear antibody (ANA), anti-double stranded DNA antibody (anti-dsDNA Ab), anti-cardiolipin antibody (aCL Ab) and anti-ß₂-glycoprotein I antibody (IgG ß₂ GPI)]. Treatment with MMI or PTU produced a significant difference in IgG aCL Ab production but not in ANA, dsDNA Ab, IgM aCL or IgG ß₂ GPI. For those treated with MMI but not those treated with PTU, ANA and anti-dsDNA Ab were positively correlated. IgG and IgM aCL Ab were positively correlated overall and for those on MMI but not PTU treatment. No significant difference was found for any of the four non organ specific antibodies in AMA positive or negative patients but there was a significant difference in IgG aCL positivity rates for ATA positive and negative patients. On the other hand, ANA negative patients were significantly more likely to have higher TBII values. These results suggest that the appearance of the non organ specific autoantibodies is probably largely a coincidental effect of polyclonal activation - except, perhaps, for IgG aCL, which may be related to treatment.

Key Words: autoantibodies • Graves’ disease • methimazole • propylthiouracil

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. S. Glaser, D. M. Styne, and for the Organization of Pediatric Endocrinologists Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective, Multicenter Study Pediatrics, March 1, 2008; 121(3): e481 - e488. [Abstract] [Full Text] [PDF]